Literature DB >> 11473109

Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice.

S Kins1, A Crameri, D R Evans, B A Hemmings, R M Nitsch, J Gotz.   

Abstract

Hyperphosphorylated isoforms of the microtubule-associated protein tau are the major components of neurofibrillary lesions in Alzheimer's disease (AD). Protein phosphatase (PP) 2A is a major phosphatase implicated in tau dephosphorylation in vitro. Dephosphorylation of tau can be blocked in vivo by okadaic acid, a potent inhibitor of PP2A. Moreover, activity of PP2A is reduced in AD brains. To elucidate the role of PP2A in tau phosphorylation and pathogenesis, we expressed a dominant negative mutant form of the catalytic subunit Calpha of PP2A, L199P, in mice by using a neuron-specific promoter. We obtained mice with high expression levels of Calpha L199P in cortical, hippocampal, and cerebellar neurons. PP2A activity in brain homogenates of transgenic mice was reduced to 66%. Endogenous tau protein was hyperphosphorylated at distinct sites including the AT8 epitope Ser-202/Thr-205, a major AD-associated tau phosphoepitope. AT8-positive tau aggregates accumulated in the soma and dendrites of cortical pyramidal cells and cerebellar Purkinje cells and co-localized with ubiquitin. Our data establish that PP2A plays a crucial role in tau phosphorylation. Our results also show that reduced PP2A activity is associated with altered compartmentalization and ubiquitination of tau, resembling a key pathological finding in AD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11473109     DOI: 10.1074/jbc.M102621200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

1.  Genetic modifiers of tauopathy in Drosophila.

Authors:  Joshua M Shulman; Mel B Feany
Journal:  Genetics       Date:  2003-11       Impact factor: 4.562

Review 2.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer's disease.

Authors:  Laurel Vana; Nicholas M Kanaan; Isabella C Ugwu; Joanne Wuu; Elliott J Mufson; Lester I Binder
Journal:  Am J Pathol       Date:  2011-09-23       Impact factor: 4.307

Review 4.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

5.  Gastrodia elata Blume (tianma) mobilizes neuro-protective capacities.

Authors:  Arulmani Manavalan; Umamaheswari Ramachandran; Husvinee Sundaramurthi; Manisha Mishra; Siu Kwan Sze; Jiang-Miao Hu; Zhi Wei Feng; Klaus Heese
Journal:  Int J Biochem Mol Biol       Date:  2012-06-03

6.  Different mechanisms account for extracellular-signal regulated kinase activation in distinct brain regions following global ischemia and reperfusion.

Authors:  Y Ho; E Logue; C W Callaway; D B DeFranco
Journal:  Neuroscience       Date:  2007-01-04       Impact factor: 3.590

7.  Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling.

Authors:  Eva Kickstein; Sybille Krauss; Paul Thornhill; Désirée Rutschow; Raphael Zeller; John Sharkey; Ritchie Williamson; Melanie Fuchs; Andrea Köhler; Hartmut Glossmann; Rainer Schneider; Calum Sutherland; Susann Schweiger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

Review 8.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

9.  Upregulation of SET expression by BACE1 and its implications in Down syndrome.

Authors:  Xiaozhu Zhang; Yili Wu; Xiaoling Duan; Wei Chen; Haiyan Zou; Mingming Zhang; Shuting Zhang; Fang Cai; Weihong Song
Journal:  Mol Neurobiol       Date:  2014-06-17       Impact factor: 5.590

10.  An update on the toxicity of Abeta in Alzheimer's disease.

Authors:  Jürgen Götz; Lars M Ittner; Nicole Schonrock; Roberto Cappai
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.